MiraQ Cardiac

Advanced Transit Time Flow Measurement Technology for Reliable Graft Verification in Cardiac Surgery

Medistim developed the MiraQ Cardiac as an advanced intraoperative Transit Time Flow Measurement (TTFM) platform designed to evaluate graft patency and blood flow during cardiac surgery. The system is widely used worldwide in coronary artery bypass grafting (CABG) procedures to provide objective real-time graft verification during surgery.

Transit Time Flow Measurement technology uses ultrasound-based flow analysis to measure real blood flow through bypass grafts intraoperatively, providing immediate feedback to the surgeon. This allows technically inadequate anastomoses, graft kinking, or flow abnormalities to be detected before completion of the procedure. The primary purpose of TTFM is to reduce early graft failure, identify grafts requiring revision, and improve long-term surgical outcomes.

The MiraQ Cardiac system simultaneously evaluates several critical parameters including flow volume (mL/min), Pulsatility Index (PI), diastolic filling percentage, and flow curve morphology. Low flow values and elevated PI measurements can provide early warning signs of technical graft issues, allowing immediate intraoperative correction. Compared with traditional visual inspection methods, TTFM provides a far more objective and quantifiable quality control standard.

The clinical importance of TTFM has been increasingly supported by numerous published studies over the past decade. Cardiovascular surgery guidelines across Europe and North America recommend intraoperative graft verification methods during CABG procedures. Clinical research has demonstrated that intraoperative revision of grafts with poor flow characteristics significantly improves postoperative graft patency rates.

One of the major strengths of the MiraQ Cardiac platform is that it combines TTFM technology with high-resolution ultrasound imaging capabilities. The system enables both functional flow assessment and anatomical visualization of grafts within a single integrated platform. This hybrid approach provides important clinical advantages, particularly during complex bypass procedures.

Medistim is widely recognized as one of the pioneering companies responsible for establishing TTFM as a standard quality assurance tool in cardiac surgery. Beyond device development, the company has contributed significantly to the academic validation and standardization of intraoperative graft assessment protocols. Today, Medistim systems are routinely used in many leading cardiovascular surgery centers worldwide.

Ease of use is another key advantage of the MiraQ Cardiac system. Surgeons can perform measurements within seconds during surgery, while real-time flow curves are displayed immediately on screen. This rapid feedback structure enhances patient safety while adding minimal additional procedural time.

The system also supports a wide range of probe configurations suitable for different vessel sizes and anatomical structures. Dedicated probes for arterial and venous grafts allow reliable measurements across various bypass configurations. In multi-vessel CABG procedures, all grafts can be systematically evaluated using standardized TTFM protocols.

Compared with alternative solutions, MiraQ Cardiac stands out through its extensive clinical validation, long-standing experience in TTFM technology, intuitive workflow, and integrated ultrasound functionality. Its ability to combine objective flow measurement with direct anatomical visualization represents a particularly important differentiating advantage.

In summary, the Medistim MiraQ Cardiac platform provides advanced intraoperative graft verification that improves surgical quality control, enhances patient safety, and contributes to better CABG outcomes. As the importance of Transit Time Flow Measurement continues to grow in modern cardiac surgery, MiraQ Cardiac remains one of the leading reference solutions in this field.